Lead Sponsor

Incyte Corporation

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•HS disease duration of at least 3 months before screening.
•Willingness to avoid pregnancy or fathering children.
•Active HS in at least 2 distinct anatomical areas.
•Participants agree NOT to use topical antiseptics on the areas affected by HS lesions during the placebo-controlled 16-week treatment period

•Draining fistula count of \> 20 at screening or baseline.
•Women who are pregnant (or who are considering pregnancy) or lactating.
•Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
•History of failure to treatment of inflammatory diseases with JAK inhibitors.
•Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
•Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.
•Laboratory values outside of the protocol-defined ranges.

Related studies

NCT06958211 · Hidradenitis Suppurativa

NCT06921850 · Hidradenitis Suppurativa

NCT05889182 · Hidradenitis Suppurativa

NCT03146676 · Hidradenitis Suppurativa

NCT05243966 · Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, and more

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa